78 related articles for article (PubMed ID: 10514901)
1. In vitro absorption studies with carvedilol using a new model with porcine intestine called BM-RIMO (Boehringer-Mannheim ring model).
Nolte K; Backfisch G; Neidlein R
Arzneimittelforschung; 1999 Sep; 49(9):745-9. PubMed ID: 10514901
[TBL] [Abstract][Full Text] [Related]
2. In vitro studies of poorly absorbed drugs using porcine intestine in the ring model RIMO.
Nolte K; Backfisch G; Neidlein R
Arzneimittelforschung; 2000 Jul; 50(7):664-8. PubMed ID: 10965427
[TBL] [Abstract][Full Text] [Related]
3. Design and in vivo evaluation of carvedilol buccal mucoadhesive patches.
Thimmasetty J; Pandey G; Babu P
Pak J Pharm Sci; 2008 Jul; 21(3):241-8. PubMed ID: 18614419
[TBL] [Abstract][Full Text] [Related]
4. Improvement of intestinal absorption of forsythoside A in weeping forsythia extract by various absorption enhancers based on tight junctions.
Zhou W; Qin KM; Shan JJ; Ju WZ; Liu SJ; Cai BC; Di LQ
Phytomedicine; 2012 Dec; 20(1):47-58. PubMed ID: 23089157
[TBL] [Abstract][Full Text] [Related]
5. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
Yedurkar P; Dhiman MK; Petkar K; Sawant K
J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549
[TBL] [Abstract][Full Text] [Related]
6. Rats with portacaval shunt as a potential experimental pharmacokinetic model for liver cirrhosis: application to carvedilol stereopharmacokinetics.
Stahl E; Baumgartner U; Henke D; Schölmerich J; Mutschler E; Spahn-Langguth H
Chirality; 1993; 5(1):1-7. PubMed ID: 8095396
[TBL] [Abstract][Full Text] [Related]
7. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity.
Feuerstein GZ; Yue TL; Cheng HY; Ruffolo RR
J Hypertens Suppl; 1993 Jun; 11(4):S41-8. PubMed ID: 8104241
[TBL] [Abstract][Full Text] [Related]
8. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement.
Schipper NG; Vârum KM; Stenberg P; Ocklind G; Lennernäs H; Artursson P
Eur J Pharm Sci; 1999 Aug; 8(4):335-43. PubMed ID: 10425384
[TBL] [Abstract][Full Text] [Related]
9. Improvement of absorption enhancing effects of n-dodecyl-beta-D-maltopyranoside by its colon-specific delivery using chitosan capsules.
Fetih G; Lindberg S; Itoh K; Okada N; Fujita T; Habib F; Artersson P; Attia M; Yamamoto A
Int J Pharm; 2005 Apr; 293(1-2):127-35. PubMed ID: 15778050
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
11. Development of mucoadhesive patches for buccal administration of carvedilol.
Vishnu YV; Chandrasekhar K; Ramesh G; Rao YM
Curr Drug Deliv; 2007 Jan; 4(1):27-39. PubMed ID: 17269915
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
13. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
[TBL] [Abstract][Full Text] [Related]
14. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
[TBL] [Abstract][Full Text] [Related]
15. Amino acids in the rat intestinal lumen regulate their own absorption from a distant intestinal site.
Mourad FH; Barada KA; Khoury C; Hamdi T; Saadé NE; Nassar CF
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G292-8. PubMed ID: 19541927
[TBL] [Abstract][Full Text] [Related]
16. Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol.
Stoschitzky K; Stoschitzky G; Brussee H; Bonelli C; Dobnig H
Cardiology; 2006; 106(4):199-206. PubMed ID: 16679760
[TBL] [Abstract][Full Text] [Related]
17. Stereoselective oxidation and glucuronidation of carvedilol in human liver and intestinal microsomes.
Ishida K; Taira S; Morishita H; Kayano Y; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2008 Jun; 31(6):1297-300. PubMed ID: 18520073
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the potential drug-drug interaction between carvedilol and clopidogrel mediated through intestinal P-glycoprotein.
Incecayir T; Ilbasmis-Tamer S; Tirnaksiz F; Degim T
Pharmazie; 2016 Aug; 71(8):472-477. PubMed ID: 29442035
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
Miki S; Masumura H; Kaifu Y; Yuasa S
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report.
Louis WJ; McNeil JJ; Workman BS; Drummer OH; Conway EL
J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S89-93. PubMed ID: 2454376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
